Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.
Milestone Pharmaceuticals, a Canada-based cardiovascular therapy developer backed by pharmaceutical firm Novo, raised $82.5m in its initial public offering yesterday after pricing its shares at $15.00 each.
The company issued 5.5 million shares on the Nasdaq Global Select Market, in the middle of the IPO’s $14 to $16 range, valuing it at $354m. Its shares briefly reached a peak of $16.42 before closing at $15.37 on its first day of trading yesterday.
Founded in 2003, Milestone is working on…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
